X-Ray Powder Diffraction and Crystallography
A molecule’s connectivity — which atoms bond to which — doesn’t change between crystal forms. Its packing does, and packing is exactly what changes a drug’s solubility, dissolution rate, stability, and even its patentability. Thermal analysis infers packing indirectly, from a transition’s energy. X-ray diffraction reads it directly.
The one idea
Every distinct crystal form of a molecule scatters X-rays into its own characteristic pattern, as unique to that packing arrangement as a fingerprint — which makes a diffractogram a reference-pattern identity test, in the same family as the IR and Raman identity checks from molecular spectroscopy, just reading packing instead of bonds.
The technique family
| Technique | What it needs | What it gives you | Typical role |
|---|---|---|---|
| X-ray powder diffraction (XRPD) | A bulk powder sample | A diffractogram — peak positions (2θ) and relative intensities unique to the crystal form | The routine compendial method for polymorph, hydrate, and salt-form identity |
| Single-crystal X-ray diffraction | One suitable single crystal | Absolute molecular structure and packing, unambiguously | Decisive when you can get it, but growing a diffraction-quality crystal is often the limiting step — rare in routine QC |
| Polarised light microscopy (PLM) | A few particles on a slide | Birefringence — a fast qualitative “is this crystalline, and does it look like the reference” | The cheap first triage before requesting XRPD |
| Solid-state NMR (ssNMR) | A bulk powder sample | Polymorph identification and quantitation, including amorphous content | The same nucleus-in-a-field physics as the solution NMR sessions earlier in the term, applied to a rigid lattice rather than a tumbling molecule in solution |
Why XRPD works
X-rays scatter off the electrons in a crystal’s repeating lattice. Where scattered waves reinforce (Bragg’s law: constructive interference at specific angles set by the lattice spacing), you get a peak; where they cancel, you don’t. Two polymorphs of the same molecule pack their unit cells differently, so their diffractograms — the whole pattern of peak positions — differ, even though every peak in both patterns comes from the identical set of atoms. An identity test compares a sample’s pattern to a reference pattern under a defined acceptance criterion (matching peak positions within a tolerance, not “looks similar”) — the same discipline the course already applied to a UV or IR spectral match.
Preferred orientation is the classic XRPD pitfall: needle- or plate-shaped crystals tend to pack non-randomly on the sample holder, distorting the relative intensities of peaks (though not their positions) — a pattern that looks like a form change on intensity alone can just be a packing artifact from how the powder was loaded.
The amorphous-content blind spot
XRPD’s peaks come from long-range crystalline order; an amorphous fraction has none, and shows up only as a broad, low hump under the crystalline peaks — invisible below roughly 5% amorphous content by routine XRPD. This is the same teaching point flagged in molecular spectroscopy: a small amorphous fraction is more soluble and less stable than the crystalline form, and it’s a classic hidden variable behind a batch that unexpectedly fails dissolution. Below XRPD’s detection limit, DSC’s glass transition, dynamic vapour sorption (extra moisture uptake an amorphous fraction sorbs), and solid-state NMR are what actually catch it — no single technique in this family is complete on its own, which is the same orthogonal-methods lesson the course keeps returning to.
Where the analyst sits
“Matches the reference pattern” needs a stated acceptance criterion before it means anything — which peaks, what 2θ tolerance, and whether intensity is scored at all given preferred orientation. A polymorph-screening report that shows a “new” pattern is a triage problem first: rule out sample-loading artifacts (grind and re-load to randomize orientation) before concluding a genuine new form has appeared.
On the job
- PLM is usually the first thing run on an unknown solid — cheap, fast, and it tells you in minutes whether XRPD is even likely to be informative (a fully amorphous sample shows no birefringence at all).
- Reading a polymorph-screening report competently means knowing which of several candidate forms is the marketed one and why — usually the most thermodynamically stable form at ambient conditions, defended with the whole technique panel (XRPD, DSC/TGA, PLM), not one trace in isolation.
- A “peak intensity looks off” observation is far more often a sample-preparation artifact (preferred orientation, particle size) than a genuine polymorphic change — know to ask about sample loading before escalating.
For discussion
- A generic manufacturer’s XRPD pattern matches the reference in peak position but not in relative intensity. Polymorph difference, or artifact? What would you check first, and what would settle it?
- Solid-state NMR detects 3% amorphous content that XRPD calls “fully crystalline.” Which result do you trust, and why does the disagreement not mean one technique is wrong?
- A batch fails dissolution with no assignable manufacturing deviation. Trace the investigation path through this section and thermal analysis to a plausible root cause.
Source note. Compendial basis: USP ⟨941⟩ (X-ray diffraction), Ph. Eur. 2.9.33 (XRPD). Single-crystal method follows standard IUCr crystallographic practice; ssNMR quantitation follows the pharmaceutical solid-state NMR literature.